About ProFibrix
ProFibrix is a company based in Leiden (Netherlands) founded in 2004 was acquired by The Medicines Company in June 2013. ProFibrix has raised $33 million across 4 funding rounds from investors including The Medicines Company, Vesalius Biocapital Partners and Index Ventures. ProFibrix operates in a competitive market with competitors including QBiotics, RevBio, MediWound, Dimension Inx and Ilya Pharma, among others.
- Headquarter Leiden, Netherlands
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$33 M (USD)
in 4 rounds
-
Latest Funding Round
$10.6 M (USD), Series B
Aug 05, 2011
-
Investors
The Medicines Company
& 4 more
-
Employee Count
Not available
-
Acquired by
The Medicines Company
(Jun 04, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ProFibrix
ProFibrix has successfully raised a total of $33M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $10.6 million completed in August 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ProFibrix
ProFibrix has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include The Medicines Company, Vesalius Biocapital Partners and Index Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology startups and entrepreneurs.
|
Locked | Locked | Locked | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Locked | Locked | Locked | |
|
Life sciences-focused VC firm investing in Europe and Canada
|
Locked | Locked | Locked |
Investor details for ProFibrix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ProFibrix
Investment portfolio details for ProFibrix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ProFibrix
Detailed financials for ProFibrix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Profibrix Comparisons
Peer comparison for ProFibrix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ProFibrix
ProFibrix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as QBiotics, RevBio, MediWound, Dimension Inx and Ilya Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecules from plant extracts are developed for medical applications.
|
|
| Locked | Locked | Locked |
Synthetic adhesives for bone and dental repair are developed.
|
|
| Locked | Locked | Locked |
Enzymatic therapies for tissue repair and regeneration are developed.
|
|
| Locked | Locked | Locked |
3D biomaterials are provided for regenerative medicine applications.
|
|
| Locked | Locked | Locked |
Biological drugs for skin and mucosa wound treatment are developed.
|
|
| Locked | Locked | Locked |
Cell-based therapeutics for cancer and immunological disorders are developed.
|
Detailed competitors of ProFibrix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Profibrix
Complete news archive for ProFibrix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ProFibrix
ProFibrix was founded in 2004 and raised its 1st funding round 3 years after it was founded.
ProFibrix is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
ProFibrix is a funded company, having raised a total of $33M across 4 funding rounds to date.
ProFibrix used its fibrinogen technology to develop and commercialize products for the hemostasis and regenerative medicine markets. Profibrixs lead biologic Fibrocaps is a formulation of fibrinogen and thrombin to aid in hemostasis during surgery. ProFibrix was acquired by The Medicines Company in Aug 2013. Fibrocaps is now known as Raplixa and received FDA approval in April 2015.
ProFibrix's top competitors include Ilya Pharma, RevBio and QBiotics.
ProFibrix has 5 investors. Key investors include The Medicines Company, Vesalius Biocapital Partners, Index Ventures, Gilde Healthcare, and Inkef.